PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few da...

Повний опис

Бібліографічні деталі

Автори:	Arianna Toscano, Maria Cinquegrani, Michele Scuruchi, Antonino Di Pino, Salvatore Piro, Viviana Ferrara, Carmela Morace, Alberto Lo Gullo, Egidio Imbalzano, Francesco Purrello, Giovanni Squadrito, Roberto Scicali, Giuseppe Mandraffino
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2022-04-01
Серія:	Biomolecules
Предмети:	PCSK9 familial hypercholesterolemia atherosclerotic injury
Онлайн доступ:	https://www.mdpi.com/2218-273X/12/4/562
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!